Timing of simvastatin treatment: No matter the time of day, does UK policy reflect the evidence?

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7432.168-b (Published 15 January 2004) Cite this as: BMJ 2004;328:168
  1. Martin G Duerden (martin@theduerdens.co.uk), senior lecturer in therapeutics,
  2. Maria D Allinson, primary care trust prescribing support pharmacist,
  3. Jo Lockett, senior data analyst
  1. Department of Medicines Management, Keele University, Staffordshire ST5 5BG

    EDITOR—Wallace et al highlight important issues on managing so called hyperlipidaemia.1 The timing of the statin dose is irrelevant, with current policy and practice not designed to deliver the clinical outcomes seen in recent drug trials.2 They studied suboptimal doses, which is common; data from the West Midlands show that 36% of patients are prescribed simvastatin 10 mg …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription